-
Mashup Score: 2THE ONCOALERT NETWORK - 11 month(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Shilpa Gupta on Urothelial Carcinoma Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab - The ASCO Post - 11 month(s) ago
2023 ASCO Annual Meeting Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASCOPost: Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab https://t.co/k80zVCFjxG…
-
-
Mashup Score: 2Ultrasound of malignant uterine mass: degenerative versus necrotic cystic manifestations and lack of structure - 11 month(s) ago
Uterine sarcomas are rare and difficult to diagnose on ultrasound, especially leiomyosarcomas diiferentiati0n from fibroids and degenerative changes. Ultrasound features suspicious of malignant fibroids are non-specific, inconsistent, and include irregular mass, irregular cystic areas, and/or rich
Categories: Latest Headlines, Oncologists2Tweet-
RT @ArturasDobilas: Ultrasound of malignant uterine mass🤔 @OncoAlert @ESGO_society https://t.co/7CoccM9KXP
-
-
Mashup Score: 1THE ONCOALERT NETWORK - 11 month(s) ago
THE ONCOALERT NETWORK
Source: THE ONCOALERT NETWORKCategories: Latest Headlines, Oncologists2Tweet-
RT @OncoAlert: Thank you very much @christine_lovly !! Anyone who has not registered for the Newsletter Do so at https://t.co/yzt83gqQkF
-
-
Mashup Score: 7Thoracic Cancer - 11 month(s) ago
Thoracic Cancer
Source: ASCOCategories: Latest Headlines, Oncologists2Tweet-
RT @ASCO: Just issued: Rapid guideline update on managing stage III #NSCLC. Read more ➡️ https://t.co/AgDF9M7tyk #lcsm #lungcancer #ASCO23…
-
-
Mashup Score: 3THE ONCOALERT NETWORK - 11 month(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @OncoAlert: The #OncoAlertTopTweet 🚨 Day 4 of #ASCO23 🌐 The OncoAlert Newsletter is Out Register at https://t.co/yzt83gqQkF Best, @weo…
-
-
Mashup Score: 3RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations - 11 month(s) ago
Abstract. Oncogenic activation of fibroblast growth factor receptor 2 (FGFR2) drives multiple cancers and represents a broad therapeutic opportunity, yet selective targeting of FGFR2 has not been achieved. While the clinical efficacy of pan-FGFR inhibitors (pan-FGFRi) validates FGFR2 driver status in FGFR2 fusion-positive intrahepatic cholangiocarcinoma, their benefit is limited by incomplete…
Categories: Latest Headlines, Oncologists2Tweet-
RT @VivekSubbiah: Our simultaneous #precisionMedicine publication @CD_AACR @AACR #ASCO23 @ASCO @OncoAlert https://t.co/gEpMgQEj7z
-
-
Mashup Score: 3THE ONCOALERT NETWORK - 11 month(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @OncoAlert: The #OncoAlertTopTweet 🚨 DAY3⃣of #ASCO23 🌐 Tweet by @OncoAlert THE NEWSLETTER IS OUT Register at https://t.co/yzt83gqQkF…
-
-
Mashup Score: 3Drug Shortages - 11 month(s) ago
Find ASCO resources related to drug shortages
Source: ASCOCategories: Latest Headlines, Oncologists2Tweet-
RT @jrgralow: Great news on @US_FDA approval of importation of cisplatin. See https://t.co/vrCgE2KKwP @asco
-
-
Mashup Score: 23THE ONCOALERT NETWORK - 11 month(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Latest Headlines, Oncologists2Tweet-
RT @OncoAlert: Dear Colleagues The @OncoAlert 🚨Newsletter comes out TOMORROW Thursday June 1st, 2023 Go to https://t.co/yzt83gqQkF To REGIS…
-
RT @OncoAlert: Thank you very much @SilvajDiogo !! Anyone who has not registered for the Newsletter Can Do so at https://t.co/THKFAIOPfb…